Most people have heard that ketamine started life as an anesthetic. What they don’t know is just how wild the journey from operating room to mental health clinic actually was. It took decades of curious researchers, a few surprising discoveries, and one landmark FDA approval to transform this battlefield drug into a genuine lifeline for people living with depression, PTSD, and other conditions that refuse to respond to conventional treatment.
At Nura Therapy, we think understanding that history matters. It helps explain why ketamine therapy works differently than anything that came before it, and why so many Fort Worth patients who felt out of options are now finding real relief.
The 1960s: A New Kind of Anesthetic
Ketamine was first synthesized in 1962 by chemist Calvin Stevens, who was working to develop a safer alternative to phencyclidine (PCP). PCP had proved too dangerous for clinical use, causing extended and unpredictable dissociative states in patients. Stevens and his colleagues at Parke-Davis needed something that worked fast, wore off quickly, and kept patients breathing on their own.
Ketamine fit the bill almost perfectly. Early trials showed it produced reliable sedation and pain relief without suppressing the respiratory system, which was a critical advantage in emergency situations. By 1970, the FDA had approved ketamine for human use as a general anesthetic. It saw action during the Vietnam War, where medics used it on the battlefield precisely because it didn’t require the kind of careful airway management that other anesthetics demanded.
For the first two decades of its existence, ketamine was essentially an anesthetic and nothing more. But a handful of clinicians started noticing something odd: some patients woke up from ketamine procedures in noticeably better moods.
The 1970s and 1980s: Early Hints of Something More
Those early mood observations didn’t go entirely unnoticed. As far back as 1973, a paper published in the journal Psychosomatics explored ketamine’s use in psychiatric contexts. A few researchers in South America began documenting what looked like antidepressant effects in patients who received it for anesthesia.
This was not mainstream thinking at the time. Psychiatry in the 1970s and 1980s was focused almost entirely on the monoamine theory of depression, the idea that mood disorders were rooted in low serotonin, dopamine, or norepinephrine. Tricyclic antidepressants and later SSRIs dominated the field. Ketamine worked through a completely different mechanism, targeting NMDA receptors in the glutamate system, and most researchers simply weren’t looking in that direction.
The 1980s brought a different kind of notoriety. Ketamine started appearing in club scenes, where it earned nicknames like “Special K” and “Vitamin K.” Its dissociative properties made it attractive as a recreational drug, which complicated its scientific reputation and made serious research harder to fund and publish. For a while, ketamine’s psychiatric potential stayed buried under its party drug image.
The 1990s: Scientists Start Paying Attention
Things began to shift in the 1990s. Researchers studying glutamate’s role in mood disorders started building a compelling case that the NMDA receptor wasn’t just a curiosity. It appeared to play a central role in how the brain processes stress, forms memories, and regulates mood. If that was true, then blocking NMDA receptors with a drug like ketamine might do something genuinely useful for people with depression.
Small studies started appearing. They weren’t large enough to change clinical practice, but they were consistent enough to attract attention. The results kept showing the same pattern: patients with treatment-resistant depression who received a single low-dose ketamine infusion reported significant improvements in mood, sometimes within hours.
That speed was astonishing to researchers. Traditional antidepressants typically require four to six weeks before patients feel any meaningful change. Here was a compound that appeared to work within a day. The question was why.
The 2000s: The Landmark Study That Changed Everything
In 2000, a research team at Yale University published a small but rigorously designed placebo-controlled trial in Biological Psychiatry. The study looked at patients with treatment-resistant major depression and gave them a single subanesthetic dose of intravenous ketamine. The results were striking. Patients who received ketamine showed rapid and significant reductions in depressive symptoms, with effects appearing within hours and lasting several days.
This was the study that legitimized ketamine research. It didn’t answer every question, but it made it impossible to dismiss the earlier findings as coincidence. The National Institute of Mental Health took notice and began funding larger investigations. A new wave of clinical trials launched across the United States and Europe.
Researchers also started piecing together the mechanism. Ketamine blocks NMDA receptors, which triggers a surge of glutamate that activates a different receptor type called AMPA. This cascade leads to increased production of brain-derived neurotrophic factor (BDNF), a protein sometimes described as fertilizer for brain cells. BDNF promotes neuroplasticity, the brain’s ability to form new connections and reorganize itself. For people whose depression had carved deep, rigid neural grooves reinforcing hopelessness and suffering, ketamine appeared to offer something no SSRI could: the biological machinery to build new pathways around the damage.
The 2010s: From Research to Real Clinics
Throughout the 2010s, ketamine therapy moved from academic research settings into clinical practice. Physicians began offering IV ketamine infusions on an off-label basis, meaning the drug was FDA-approved but not specifically approved for depression treatment. This is actually common in medicine, and off-label use is entirely legal when a licensed physician determines it’s appropriate for a patient.
The conditions being treated expanded beyond depression. Researchers and clinicians found compelling evidence for ketamine’s effectiveness in PTSD, anxiety, OCD, bipolar depression, chronic pain, and suicidal ideation. That last application was particularly significant. Ketamine’s rapid action made it potentially lifesaving in crisis situations where patients couldn’t wait weeks for a traditional medication to kick in.
During this decade, the pharmaceutical company Janssen began developing esketamine, the S-enantiomer of ketamine, as a nasal spray for treatment-resistant depression. This formulation, eventually branded as Spravato, went through a series of phase III clinical trials and generated enough data for a formal FDA application.
2019 and Beyond: FDA Approval and a New Era
In March 2019, the FDA approved esketamine nasal spray under the brand name Spravato for adults with treatment-resistant depression, making it the first genuinely new class of antidepressant approved in decades. Unlike every antidepressant that preceded it, Spravato doesn’t touch the serotonin system. It works entirely through the glutamate pathway, representing a true paradigm shift in how psychiatry understands and treats depression.
The approval validated what clinicians using IV ketamine had been observing for years. It also opened doors for insurance coverage that simply hadn’t existed before, making treatment more accessible for patients who needed it most.
Research has continued expanding since then. Studies have investigated ketamine’s potential for conditions like substance use disorder, where it appears to interrupt addictive neural patterns, and for chronic pain syndromes where conventional pain management has failed. The history of ketamine treatment is, in other words, still being written.
What the History Tells Us About How Ketamine Works
Here’s what makes this history meaningful rather than just interesting: understanding where ketamine came from explains why it works for patients who’ve exhausted every other option. The conditions that respond to ketamine share a common feature. They involve rigid, dysfunctional brain circuitry that conventional medications, which mostly adjust neurotransmitter levels, simply can’t restructure.
Ketamine doesn’t just adjust neurotransmitters. It promotes the growth of new neural connections. Think of traditional antidepressants as trying to fix a crumbling road by patching potholes, while ketamine builds an entirely new route. That’s why people with treatment-resistant depression, years of suffering behind them, sometimes report noticeable change after a single session.
How Nura Therapy Fits Into This Story
Fort Worth has its own place in this evolving history. At Nura Therapy, our physician-owned clinic was founded specifically because our team saw how many patients were falling through the cracks of conventional psychiatry. Conditions like depression, PTSD, anxiety, OCD, chronic pain, and bipolar disorder don’t always yield to first-line treatments, and the people living with them deserve access to what decades of research have made possible.
Our treatments include IV ketamine infusions, Spravato, and ketamine-assisted psychotherapy, each grounded in the same science that researchers began uncovering in those early 2000 studies. Every protocol we use reflects current best practices, and every patient receives individualized care from a board-certified physician.
The history of ketamine treatment is ultimately a story about what happens when medicine stops assuming that the first generation of treatments defines the ceiling of what’s possible. For patients in Fort Worth who’ve been told there’s nothing left to try, that history carries a lot of hope.
Ready to Learn More?
Nura Therapy
4622 Saint Amand Circle
Fort Worth, TX 76126
Phone: Contact for consultation
You’ve carried this long enough. Let’s figure out what’s possible together.
Legal Disclaimer
The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare provider before beginning any new treatment.